Elevated soluble cd8 in the synovial fluid from patients with rheumatoid arthritis

✍ Scribed by A. B. Carpenter; C. H. Eisenbeis; S. Carrabis; M. C. Brown; S. H. Ip

• Publisher: John Wiley and Sons
• Year: 1990
• Tongue: English
• Weight: 483 KB
• Volume: 4
• Category: Article
• ISSN: 0887-8013
• DOI: 10.1002/jcla.1860040505

✦ Synopsis

Abstract

Suppressor/cytotoxic T cells express the surface marker CD8, which can be measured in a soluble form in culture supernatants of activated human lymphocytes. Using a sandwich immunoassay, we assessed the levels of soluble CD8 (sCD8) in serum from patients with rheumatoid arthritis (RA; n = 82), patients with degenerative joint disease (DJD; n = 40), and healthy controls. There were no differences in serum sCD8 levels among these groups. In contrast, the levels of soluble CD8 in the synovial fluid (SF) from patients with RA (n = 53) were significantly increased compared with the levels in 23 samples from patients with DJD (821 ± 110 U/ml versus 213 ± 13 U/ml, p < 0.001). Synovial fluid sCD8 levels in the RA group were strikingly elevated, to a maximum value of 5,026 U/ml. In the majority of RA SF specimens (39 of 53), the values were significantly higher in the SF than the serum. Although the RA group had higher values of sCD8, such values were not significantly correlated with measured laboratory or clinical parameters. Current clinical and laboratory methods of evaluating patients may not be adequate in dealing with the complexity and heterogeneity of RA. Soluble CD8 values may be useful in further grouping patients with this disease.